Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.08.2022 | Case report

Bosutinib

Various toxicities and lack of efficacy following off-label use: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Claudiani S, et al. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. European Journal of Haematology 109: 90-99, No. 1, Jul 2022. Available from: URL: http://doi.org/10.1111/ejh.13775 Claudiani S, et al. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. European Journal of Haematology 109: 90-99, No. 1, Jul 2022. Available from: URL: http://​doi.​org/​10.​1111/​ejh.​13775
Metadaten
Titel
Bosutinib
Various toxicities and lack of efficacy following off-label use: 5 case reports
Publikationsdatum
01.08.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-20568-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Regorafenib

Case report

Multiple drugs